SunWay Biotech Co

SunWay Biotech Co Debt

The Debt of SunWay Biotech Co (1271.TWO) as of Oct 20, 2026 is 408.86 M TWD. In the previous year, Debt was 249.85 M TWD — a change of 63.64% (higher).

Debt

408.86 MTWD

YoY

63.64%

Last updated:

In 2025, SunWay Biotech Co's total debt was 408.86 M TWD, a 63.64% change from the 249.85 M TWD total debt recorded in the previous year.

The SunWay Biotech Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
19.68 M TWD
Jan 1, 2020
16.95 M TWD
Jan 1, 2021
20.69 M TWD
Jan 1, 2022
71.34 M TWD
Jan 1, 2023
303.55 M TWD
Jan 1, 2024
249.85 M TWD
Jan 1, 2025
408.86 M TWD
The SunWay Biotech Co Debt history
YEARDebtYoY
408.86 MTWD+63.64%
249.85 MTWD-17.69%
303.55 MTWD+325.49%
71.34 MTWD+244.88%
20.69 MTWD+22.04%
16.95 MTWD-13.88%
19.68 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding SunWay Biotech Co's Debt Structure

SunWay Biotech Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing SunWay Biotech Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to SunWay Biotech Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in SunWay Biotech Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about SunWay Biotech Co stock

Debt of SunWay Biotech Co is 408.86 M TWD in 2025.

Debt of SunWay Biotech Co changed from 249.85 M TWD to 408.86 M TWD, representing a 63.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's SunWay Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co